Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
NCT06178432
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
6
Enrollment
OTHER
Sponsor class
Conditions
Pompe Disease (Late-onset)
Interventions
GENETIC:
CRG003 injection
Sponsor
Huashan Hospital